Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Longitudinal cognitive performance of participants with sporadic early onset Alzheimer's disease from LEADS.

Longitudinal cognitive performance of participants with sporadic early onset Alzheimer's disease from LEADS. Alzheimer's & dementia : the journal of the Alzheimer's Association Hammers, D. B., Eloyan, A., Taurone, A., Thangarajah, M., Gao, S., Beckett, L., Polsinelli, A. J., Kirby, K., Dage, J. L., Nudelman, K., Aisen, P., Reman, R., La Joie, R., Lagarde, J., Atri, A., Clark, D., Day, G. S., Duara, R., Graff-Radford, N. R., Grant, I., Honig, L. S., Johnson, E. C., Jones, D. T., Masdeu, J. C., Mendez, M. F., Womack, K., Musiek, E., Onyike, C. U., Riddle, M., Rogalski, E., Salloway, S., Sha, S. J., Turner, R. S., Wingo, T. S., Wolk, D. A., Carrillo, M. C., Rabinovici, G. D., Dickerson, B. C., Apostolova, L. G. 2024

Abstract

Early-onset Alzheimer's disease (EOAD) manifests prior to the age of 65, and affects 4%-8% of patients with Alzheimer's disease (AD). The current analyses sought to examine longitudinal cognitive trajectories of participants with early-onset dementia.Data from 307 cognitively normal (CN) volunteer participants and those with amyloid-positive EOAD or amyloid-negative cognitive impairment (EOnonAD) were compared. Cognitive trajectories across a comprehensive cognitive battery spanning 42 months were examined using mixed-effects modeling.The EOAD group displayed worse cognition at baseline relative to EOnonAD and CN groups, and more aggressive declines in cognition over time. The largest effects were observed on measures of executive functioning domains, while memory declines were blunted in EOAD.EOAD declined 2-4× faster than EOnonAD, and EOAD pathology is not restricted to memory networks. Early identification of deficits is critical to ensure that individuals with sporadic EOAD can be considered for treatment using disease-modifying medications.Represents the most comprehensive longitudinal characterization of sporadic EOAD to date. The trajectory of cognitive declines was steep for EOAD participants and worse than for other groups. Executive functioning measures exhibited the greatest declines over time in EOAD.

View details for DOI 10.1002/alz.14439

View details for PubMedID 39713873